Ventilator Care — Cost, Top Hospitals & Success Rates | MyMedicPlus

Mechanical ventilation (MV) is a life-sustaining intervention that provides partial or complete support for a patient's breathing when the respiratory system is unable to maintain adequate gas exchange — oxygenation (delivery of oxygen to the blood) and ventilation (removal of carbon dioxide) — or when respiratory muscle effort is insufficient to sustain the work of breathing. A ventilator — a sophisticated pneumatic device — delivers pressurised gas (air, oxygen, or blended mixtures) into the patient's airways through an endotracheal tube, supraglottic airway, tracheostomy, or non-invasive mask interface, providing carefully controlled breaths at set volumes, pressures, rates, and oxygen concentrations.

Approximately 800,000 adult patients receive mechanical ventilation annually in the United States — making it one of the most commonly performed life-sustaining interventions in intensive care medicine. Despite this prevalence, MV is not a treatment in itself: it is a supportive bridge that buys time for the underlying condition causing respiratory failure to resolve, while protecting the patient from the consequences of inadequate gas exchange.

The history of modern mechanical ventilation is rooted in the polio epidemics of the 1950s, when negative-pressure "iron lung" ventilators kept thousands of paralysed patients alive. The development of positive-pressure ventilation through endotracheal intubation transformed the practice of medicine, enabling modern anaesthesia, cardiac surgery, and intensive care. The subsequent decades brought the recognition that mechanical ventilation itself causes lung injury — ventilator-induced lung injury (VILI) — leading to the paradigm shift to lung-protective ventilation strategies validated by the landmark ARDSNet ARMA trial (NEJM, 2000), which demonstrated a 22% relative mortality reduction using low tidal volume (6 mL/kg ideal body weight) versus conventional tidal volumes in ARDS.

Modern ventilator care encompasses not only the management of the ventilator settings but a holistic bundle of ICU practices including analgesia-first sedation (minimising oversedation), daily awakening and spontaneous breathing trials (to identify readiness for extubation), prone positioning for severe ARDS, early mobility, and lung-protective ventilation — collectively embodied in the ABCDEF (A2F) ICU Liberation Bundle, which has been shown in multicentre studies to reduce ICU length of stay, MV duration, and delirium when consistently applied.

Mechanical ventilation is indicated across a wide range of acute and chronic conditions causing respiratory failure or airway compromise:

• Acute respiratory distress syndrome (ARDS): A life-threatening syndrome defined by the Berlin criteria (2012) as acute onset, PaO₂/FiO₂ ratio <300 mmHg (mild), <200 mmHg (moderate), or <100 mmHg (severe), bilateral chest infiltrates on imaging, and non-cardiogenic pulmonary oedema. Common triggers include pneumonia, sepsis, aspiration, trauma, and pancreatitis. ARDS carries a mortality rate of 30–45% in severe cases despite optimal ventilatory management.
• Severe community-acquired and hospital-acquired pneumonia: Infectious consolidation causing hypoxaemic respiratory failure refractory to supplemental oxygen. Bacterial, viral (including influenza, SARS-CoV-2), and fungal pneumonias can all progress to respiratory failure requiring intubation and MV.
• COPD exacerbation with respiratory acidosis: Acute-on-chronic hypercapnic respiratory failure (PaCO₂ >45 mmHg, pH <7.35) with increasing dyspnoea and respiratory muscle fatigue. Non-invasive ventilation (BiPAP) is the preferred initial modality, reserving invasive MV for failures of NIV or those with impaired consciousness.
• Post-operative respiratory support: Patients recovering from major cardiac surgery (open-heart surgery, aortic root replacement), thoracic surgery, prolonged abdominal surgery, or neurosurgery typically require MV for hours to days post-operatively until anaesthetic agent clearance, normothermia, and haemodynamic stability are achieved.
• Neuromuscular causes of respiratory failure: Guillain-Barré syndrome (acute demyelinating polyneuropathy causing ascending weakness), myasthenia gravis crisis, amyotrophic lateral sclerosis (ALS), high cervical spinal cord injury, and critical illness myopathy/neuropathy all impair the respiratory muscles without affecting the lungs directly. Elective early intubation is preferred before respiratory arrest occurs.
• Status asthmaticus: Life-threatening asthma refractory to maximal bronchodilator therapy. MV in asthma is technically challenging due to severe bronchospasm causing high airway resistance, air trapping (intrinsic PEEP), and risk of barotrauma. A "permissive hypercapnia" strategy with low respiratory rates and extended expiratory time is employed to prevent dynamic hyperinflation.
• Acute brain injury: Severe traumatic brain injury (GCS <8), large ischaemic stroke, or status epilepticus may require intubation and MV for airway protection (inability to protect the airway from aspiration due to impaired consciousness), controlled hyperventilation to reduce intracranial pressure acutely, and facilitation of sedation during ICP monitoring and neurological interventions.
• Shock states: Septic shock, cardiogenic shock, and haemorrhagic shock can progress to respiratory failure from multiorgan dysfunction. MV reduces the oxygen consumption of the respiratory muscles (up to 40% of total body oxygen consumption in severe respiratory distress), redistributing oxygen delivery to other vital organs.
• Drug overdose with respiratory depression: Opioid overdose, benzodiazepine toxicity, and other CNS depressant toxidromes may cause respiratory depression requiring intubation and MV until the drug is metabolised or antagonised (naloxone for opioids; flumazenil for benzodiazepines in selected cases).

The decision to initiate mechanical ventilation requires clinical judgement integrating physiological parameters, trajectory of deterioration, patient goals, and available respiratory support modalities:

• Clinical indications for intubation and invasive MV: Inability to protect the airway (loss of gag reflex, GCS <8 or rapidly declining), respiratory rate >35 breaths per minute with signs of impending respiratory muscle fatigue (accessory muscle use, paradoxical abdominal movement, diaphoresis), PaO₂ <60 mmHg on FiO₂ >0.5 (oxygen fraction >50%), PaCO₂ >50 mmHg with pH <7.25 despite maximal medical management, and haemodynamic instability with declining mental status.
• Trials of non-invasive support first: In alert, cooperative patients with adequate airway protection, a trial of non-invasive ventilation (BiPAP), continuous positive airway pressure (CPAP), or high-flow nasal cannula (HFNC) at 40–60 L/min should be attempted before proceeding to intubation. NIV avoids intubation in approximately 50% of COPD exacerbations and 30–40% of hypoxaemic respiratory failure cases. Patients should be reassessed within 1–2 hours — failure to improve (worsening pH, respiratory rate, oxygen requirement, or conscious level) should prompt intubation without further delay.
• Tracheostomy for prolonged MV: When MV is anticipated to continue beyond 7–10 days — as in patients with severe TBI, high cervical SCI, or rapidly progressive neuromuscular disease — percutaneous or surgical tracheostomy is recommended over prolonged translaryngeal intubation. Tracheostomy improves patient comfort, facilitates weaning, reduces sedation requirements, enables oral feeding and communication, and decreases subglottic stenosis and tracheal injury risk compared to prolonged oral intubation.
• Goals of care discussion: Before initiating MV, patient wishes regarding life-sustaining treatment should be explored. Patients with terminal illness, severe irreversible brain injury, or end-stage disease may have advance directives declining mechanical ventilation. A time-limited trial of MV with reassessment at 48–72 hours can be appropriate in cases of clinical uncertainty, with palliative care involvement for symptom management if the decision is made to withdraw support.

Modern ventilator care encompasses a spectrum of modalities and strategies tailored to the underlying condition and respiratory physiology:

1. Lung-protective ventilation (LPV) — ARDSNet protocol: The cornerstone of invasive MV in ARDS. Key parameters: tidal volume (Vt) 6 mL/kg ideal body weight (IBW) — not actual body weight — with a goal of plateau airway pressure (Pplat) <30 cmH₂O to minimise overdistension (volutrauma/barotrauma); PEEP (positive end-expiratory pressure) titrated to the PEEP/FiO₂ table to maintain alveolar recruitment and reduce atelectrauma; permissive hypercapnia (accepting PaCO₂ up to 60–70 mmHg) if needed to achieve tidal volume targets. The ARMA trial demonstrated a 22% relative mortality reduction in ARDS with 6 mL/kg Vt versus 12 mL/kg, establishing LPV as mandatory standard of care.
2. Ventilator modes: Volume-controlled ventilation (VCV) delivers a fixed tidal volume with variable peak airway pressure; pressure-controlled ventilation (PCV) delivers a fixed inspiratory pressure with variable tidal volume — preferred when pressure-limiting is paramount. Pressure support ventilation (PSV) supports the patient's own inspiratory effort — the main mode used for weaning. SIMV (synchronized intermittent mandatory ventilation) delivers mandatory breaths plus allows spontaneous supported breaths — largely replaced by full assist-control plus PSV titration for weaning. Airway pressure release ventilation (APRV) maintains high mean airway pressure for recruitment with brief releases for CO₂ washout — used for refractory ARDS in some centres.
3. Non-invasive ventilation (NIV/BiPAP): Bi-level positive airway pressure delivered via full-face or nasal mask or helmet. Provides inspiratory support (IPAP) plus expiratory PEEP (EPAP) without endotracheal intubation. First-line therapy for acute exacerbations of COPD with hypercapnia (Cochrane evidence: reduces intubation rate by ~60%, mortality by ~50% vs standard care), acute cardiogenic pulmonary oedema, and immunocompromised patients with respiratory failure (where intubation carries particularly high infection risk).
4. High-flow nasal cannula (HFNC): Delivery of humidified, heated oxygen at flow rates of 30–60 L/min via comfortable nasal prongs, generating physiological PEEP (approximately 1–2 cmH₂O per 10 L/min) and a high FiO₂ (>0.9 at 60 L/min). The FLORALI trial (NEJM, 2015) demonstrated that HFNC reduced intubation rates and 90-day mortality compared to conventional oxygen in moderate-to-severe hypoxaemic respiratory failure (P/F ratio <300). The ROX index (SpO₂/FiO₂ divided by respiratory rate) ≥4.88 at 12 hours predicts HFNC success.
5. Prone positioning for severe ARDS: Placing patients with moderate-to-severe ARDS (P/F <150 mmHg on PEEP >5 cmH₂O, FiO₂ >0.6) in the prone (face-down) position for 16–18 hours per day reduces dependent atelectasis, improves ventilation-perfusion matching, and redistributes lung stress more homogeneously. The PROSEVA trial (NEJM, 2013) demonstrated a dramatic 63% relative mortality reduction (32.8% vs 16.0% at 28 days) with prone positioning in severe ARDS — one of the largest mortality benefits ever demonstrated in critical care. It is now a mandatory standard of care for severe ARDS in guideline-concordant ICUs.
6. Neuromuscular blockade (NMB) for ARDS: Cisatracurium continuous infusion is used in severe ARDS to eliminate patient-ventilator dyssynchrony (spontaneous breathing effort that generates injurious transpulmonary pressures — P-SILI) and facilitate prone positioning. The ACURASYS trial suggested a survival benefit; the ROSE trial (NEJM, 2019) showed no benefit with routine early NMB versus lighter sedation. Current guidance restricts NMB to cases with severe dyssynchrony, refractory hypoxaemia, or requirements for prone positioning where patient cooperation is inadequate.
7. Veno-venous ECMO (VV-ECMO): Extracorporeal membrane oxygenation provides gas exchange outside the body for patients with refractory hypoxaemia unresponsive to optimal MV and adjunctive strategies. Blood is drained from the venous system, oxygenated through a membrane oxygenator, and returned to the venous circulation. The EOLIA trial (NEJM, 2018) did not demonstrate a statistically significant 60-day mortality benefit for VV-ECMO versus conventional MV, though crossover from control to ECMO was high. ECMO is reserved for carefully selected patients at ECMO-capable centres with severe ARDS (P/F <80 despite optimal MV) after specialist consultation.
8. Weaning protocol and spontaneous breathing trials (SBT): Daily assessment for readiness to wean: FiO₂ <0.4, PEEP <5–8 cmH₂O, haemodynamic stability, absence of active sedation, adequate cough and secretion management. Once criteria are met, a 30-minute SBT using T-piece (breathing circuit disconnected, patient breathes against ambient resistance) or minimal PSV (5–8 cmH₂O) is performed. Failure criteria include: SpO₂ <90%, respiratory rate >35, heart rate or BP change >20%, distress. The Rapid Shallow Breathing Index (RSBI) = respiratory rate / tidal volume <105 breaths/min/L predicts extubation success. Extubation to HFNC or prophylactic NIV post-extubation reduces re-intubation rates in high-risk patients (HiLo trial, LANCE trial evidence).

When appropriately applied, mechanical ventilation is a life-saving intervention that enables recovery from otherwise fatal conditions:

• Life-sustaining gas exchange: MV maintains adequate oxygenation (SpO₂ >90%, PaO₂ >60 mmHg) and CO₂ clearance in patients who cannot do so independently, preventing hypoxic cardiac arrest and death from respiratory failure. Without MV, severe ARDS, pulmonary oedema, or neuromuscular respiratory failure would be universally fatal.
• Respiratory muscle rest and recovery: Critically ill patients expend 30–40% of their total oxygen consumption on the work of breathing during respiratory failure. MV offloads this burden, allowing the respiratory muscles to rest, recover from fatigue, and ultimately regain sufficient strength for independent breathing.
• Mortality reduction with lung-protective ventilation: The ARDSNet ARMA trial established a 22% relative reduction in 28-day mortality (39.8% vs 31.0%) with 6 mL/kg IBW versus 12 mL/kg tidal volumes in ARDS — the first and most influential example of a ventilatory strategy improving patient survival. The PROSEVA prone positioning trial added a further 63% relative mortality reduction in severe ARDS. Together, these interventions have transformed ARDS prognosis over the past two decades.
• Facilitation of other life-saving interventions: MV enables general anaesthesia for emergency surgery (abdominal, cardiac, neurosurgical), safe performance of invasive procedures (bronchoscopy, broncho-alveolar lavage, endoscopy), and allows high-dose sedation and analgesia for painful procedures or severe agitation without respiratory compromise.
• Controlled neurological management: In TBI and post-cardiac arrest, MV enables precise control of PaCO₂ (targeting 35–40 mmHg to maintain cerebral autoregulation), FiO₂ (targeting normoxia, avoiding hyperoxia which worsens reperfusion injury), and sedation depth — key elements of neuroprotective critical care.
• Non-invasive ventilation benefits: NIV in COPD exacerbation reduces the need for intubation by approximately 60% and reduces ICU and hospital mortality by approximately 50%, while avoiding the complications of invasive MV (ventilator-associated pneumonia, tracheal injury, neuromuscular weakness). In acute cardiogenic pulmonary oedema, CPAP reduces the need for intubation and improves oxygenation within 30 minutes of application.

Mechanical ventilation carries significant complications — the most serious of which are caused by MV itself rather than the underlying disease. Prevention of these iatrogenic complications is a major focus of modern ICU care:

• Ventilator-associated pneumonia (VAP): The most common and serious infectious complication of invasive MV. Defined as pneumonia developing >48 hours after endotracheal intubation, caused by aspiration of oropharyngeal secretions colonised by nosocomial pathogens (Pseudomonas aeruginosa, Acinetobacter, MRSA). Incidence: 5–15 events per 1,000 ventilator-days; mortality attributable to VAP: 13–22%. Prevention (VAP bundle): head-of-bed elevation at 30–45°, subglottic secretion drainage (suction above ETT cuff), oral decontamination with chlorhexidine, daily sedation interruption, and minimising MV duration through protocolised weaning. ESICM VENTILA Group and CDC guidelines provide evidence-based VAP prevention bundles.
• Ventilator-induced lung injury (VILI): MV with excessive volumes (volutrauma) or pressures (barotrauma) causes additional lung injury beyond the underlying condition. Four mechanisms: volutrauma (overdistension of open alveoli), barotrauma (excess pressure causing alveolar rupture — pneumothorax, pneumomediastinum, subcutaneous emphysema), atelectrauma (cyclic opening and collapse of atelectatic lung units), and biotrauma (mechanical stretch activating alveolar macrophages, releasing cytokines that drive systemic inflammatory response). Lung-protective ventilation (low Vt, appropriate PEEP) is the primary preventive strategy.
• ICU-acquired weakness (ICUAW): A neuromuscular complication of critical illness and prolonged MV causing profound diffuse weakness affecting respiratory and limb muscles. Caused by critical illness polyneuropathy (CIP), critical illness myopathy (CIM), or both. Risk factors include prolonged corticosteroid use, aminoglycoside antibiotics, neuromuscular blocking agents, and immobility. ICUAW delays weaning from MV, prolongs ICU stay, and significantly impairs 6- and 12-month functional outcomes. Early active mobilisation in the ICU (ABCDE bundle) reduces ICUAW incidence and severity.
• Upper airway injury from endotracheal tube: Prolonged translaryngeal intubation causes laryngeal oedema, vocal cord paresis, laryngeal ulceration, and tracheal stenosis. High-volume, low-pressure ETT cuffs (target cuff pressure 20–30 cmH₂O) minimise mucosal ischaemia. Post-extubation stridor occurs in 10–15% of patients; treated with nebulised adrenaline and IV dexamethasone. Subglottic tracheal stenosis is a late complication in approximately 1–2% of prolonged intubation (>7 days) and may require dilation or tracheal resection months after ICU discharge.
• Oxygen toxicity: Prolonged exposure to high FiO₂ (>0.6 for >24–48 hours) generates reactive oxygen species causing oxidative alveolar cell damage. Hyperoxia worsens VILI and is independently associated with increased ICU mortality in observational studies. Conservative oxygen therapy targeting SpO₂ 90–96% (not 100%) and minimising FiO₂ through PEEP titration are current best practices.
• Haemodynamic compromise: Positive-pressure ventilation increases intrathoracic pressure, reducing venous return to the right heart and cardiac output — particularly with high PEEP levels. Careful fluid status assessment and vasopressor titration are required to maintain mean arterial pressure and organ perfusion during MV.
• Psychological trauma and post-ICU syndrome: Surviving patients who received prolonged MV frequently experience post-intensive care syndrome (PICS) — a constellation of post-traumatic stress disorder (PTSD, incidence 20–30%), cognitive impairment, and physical deconditioning persisting months to years after ICU discharge. Memory of ICU experiences including intubation, paralysis, delirium, and nightmares contributes significantly to psychological morbidity. ICU diaries (written by nurses and families during admission) reduce PTSD incidence after ICU discharge.

Successful liberation from mechanical ventilation requires a structured, protocolised approach to weaning and extubation, followed by comprehensive post-ICU rehabilitation:

• Daily readiness assessment (awakening and breathing trials): The ABCDEF Liberation Bundle specifies that every ventilated patient should undergo daily coordinated: (A) Assess, prevent, and manage pain; (B) Spontaneous Breathing Trial (SBT) — when criteria are met; (C) Choice of analgesia and sedation (analgesia-first, lightest effective sedation); (D) Delirium — assess, prevent, manage; (E) Early mobility and exercise; (F) Family engagement and empowerment. The landmark ABC trial (Lancet, 2008) demonstrated that paired daily awakening trials plus SBTs reduced MV duration by approximately 3 days and reduced ICU and hospital mortality.
• Spontaneous Breathing Trial (SBT) protocol: Once weaning readiness criteria are met (FiO₂ <0.4, PEEP <5–8 cmH₂O, haemodynamic stability without vasopressor escalation, adequate cough, manageable secretions), a 30–120 minute SBT on minimal PSV (5–8 cmH₂O) or T-piece is performed under close observation. Successful SBT: stable SpO₂, RR <35 bpm, RSBI <105, no distress, haemodynamic stability. Approximately 70–80% of patients passing SBT are successfully extubated on the first attempt.
• Extubation and post-extubation support: Extubation proceeds after SBT success, a protected cough (ability to cough and manage secretions), and absence of excessive respiratory secretions requiring continuous suctioning. High-risk patients (age >65, cardiac failure, BMI >30, weak cough, stridor history) benefit from prophylactic post-extubation HFNC (HiLo trial) or NIV (LANCE trial) to reduce re-intubation risk.
• Tracheostomy care and weaning: Patients requiring >7–10 days of MV undergo percutaneous or surgical tracheostomy to facilitate long-term weaning, communication, oral feeding, and rehabilitation. Tracheostomy weaning involves progressive reduction in ventilatory support, speaking valve (Passy-Muir) trials for communication, and capping trials (occluding the tracheostomy tube) to assess readiness for decannulation.
• Early mobility and physiotherapy: Physical therapy commencing during the ICU phase — even for ventilated patients — reduces ICUAW, delirium duration, and MV duration. The TEAM trial (NEJM, 2022) demonstrated that very early, goal-directed physiotherapy (passive range of motion to active ambulation with ventilator) significantly reduced functional dependency at 6 months. Occupational therapy addresses activities of daily living; speech-language pathology addresses post-extubation dysphagia (affecting up to 40% of patients after prolonged intubation) and communication deficits.
• Post-ICU follow-up: An expanding evidence base supports structured post-ICU follow-up clinics at 3 and 12 months. These clinics screen for PICS — physical deconditioning, cognitive impairment, and PTSD — with referral to pulmonary rehabilitation (for those with residual respiratory impairment), neuropsychology (cognitive rehabilitation), mental health services, and primary care providers. Patients discharged with tracheostomy or home NIV require community specialist nursing and repeat pulmonary function assessment.

Mechanical ventilation and ICU care are among the most resource-intensive interventions in modern medicine, generating substantial direct and indirect costs:

• ICU daily bed cost: Average ICU daily costs vary dramatically by country: approximately USD 3,500–6,000 in the USA; GBP 2,000–3,500 in the UK; EUR 1,500–2,500 in Western Europe; USD 400–1,200 in India; USD 500–1,000 in Thailand. The average episode of care for a ventilated ARDS patient in the USA costs approximately USD 30,000–100,000, depending on ICU length of stay and comorbidities.
• Mechanical ventilator equipment costs: Modern ICU ventilators (Dräger Evita, Hamilton C6, Servo-i, GE Carestation) cost USD 30,000–80,000 to purchase, with annual maintenance contracts adding USD 5,000–15,000. In resource-limited settings, simpler transport or basic ICU ventilators at USD 3,000–15,000 may be appropriate. High-flow nasal cannula therapy (HFNC) systems cost USD 5,000–15,000 for the device and USD 50–150 per circuit per patient per use.
• Tracheostomy: Percutaneous dilatational tracheostomy — performed at the bedside in the ICU — costs USD 800–2,500 in disposables and physician fees in the USA, compared to USD 4,000–8,000 for surgical tracheostomy under general anaesthesia in the operating theatre. Tracheostomy tube replacement, suctioning equipment, and specialist nursing contribute ongoing costs.
• ECMO costs: VV-ECMO for severe ARDS adds enormous incremental cost — the ECMO circuit, cannulae, oxygenator, and pump (USD 20,000–50,000 in disposables), plus the requirement for 24/7 specialist ECMO perfusionist coverage, result in total ECMO-related costs of USD 50,000–150,000+ for an average ECMO run of 10–14 days.
• Staffing intensity: ICU staffing — requiring registered nurses in a 1:1 or 1:2 patient ratio, respiratory therapists, and dedicated intensivists — accounts for 50–60% of ICU operating costs. In the USA, daily staffing cost per ICU bed is USD 2,000–4,000. High-volume, academic medical centre ICUs with closed intensivist-led models achieve better outcomes at comparable cost to lower-volume units.
• Indirect costs and long-term burden: Post-ICU survivors of prolonged MV — particularly those with ARDS, ICUAW, or PICS — require long-term rehabilitation, lost productivity during recovery, home adaptations, and ongoing medical follow-up. US studies estimate the total societal cost (direct plus indirect) of a major ARDS hospitalisation at USD 150,000–300,000 over 12 months. Caregiver burden is also substantial — family members providing informal care after ICU discharge report depression rates of 30–40%.
• Global access inequity: Access to mechanical ventilation is severely limited in low-income countries. WHO estimates that fewer than 10% of global critical care needs are met in sub-Saharan Africa and South Asia. The COVID-19 pandemic exposed catastrophic ventilator shortages. Expanding access to non-invasive modalities (NIV, HFNC) — which are far less expensive and staff-intensive than invasive MV — is a public health priority in resource-constrained settings.

The evolution of respiratory support has produced multiple modalities that can prevent or supplement invasive MV, or support patients transitioning away from the ventilator:

• High-flow nasal cannula (HFNC) oxygen therapy: HFNC delivers heated, humidified oxygen at 30–60 L/min flows, generating low levels of physiological PEEP (2–5 cmH₂O), washout of nasopharyngeal dead space, and FiO₂ up to 0.95. Well-tolerated, enabling communication and oral nutrition. The FLORALI trial and multiple meta-analyses support HFNC as the preferred initial oxygen modality for moderate-to-severe hypoxaemic respiratory failure without hypercapnia, potentially avoiding intubation in up to 40% of patients. The ROX index guides decision to escalate to NIV or intubation.
• Non-invasive ventilation (BiPAP/CPAP): NIV has the strongest evidence for COPD exacerbation with acute hypercapnic respiratory failure — reducing intubation rates by ~60% and mortality by ~50% versus standard oxygen therapy (Cochrane, 2017). CPAP is preferred for acute cardiogenic pulmonary oedema, reducing left ventricular afterload and pulmonary oedema rapidly. NIV is the preferred mode for home management of chronic hypercapnic COPD, obesity hypoventilation syndrome, and neuromuscular diseases (ALS, Duchenne muscular dystrophy) using domiciliary bilevel devices.
• Awake prone positioning: Non-intubated COVID-19 patients with moderate-to-severe hypoxaemia managed with HFNC or NIV can be placed prone while awake, improving oxygenation by mechanisms similar to intubated prone positioning. Multiple observational studies and the PROSELF trial showed modest reductions in intubation rates with awake proning, with best evidence supporting its use in combination with HFNC.
• Home mechanical ventilation: Patients with stable chronic hypercapnic respiratory failure — including those with ALS, spinal muscular atrophy, high-level SCI, or severe COPD — can be managed with long-term home NIV or invasive MV via tracheostomy. Home ventilators (Trilogy, Astral, Lumis BiPAP) are significantly smaller, quieter, and more patient-friendly than ICU ventilators. Appropriate patient selection, caregiver training, and community respiratory support services are essential for safe home ventilator management.
• Palliative care and ventilator withdrawal: For patients with irreversible underlying conditions — severe brain damage with no prospect of meaningful recovery, end-stage cancer, terminal COPD — withdrawal of mechanical ventilation is an ethical, legally supported, and increasingly common decision made collaboratively with patients (where competent) and families, guided by palliative care specialists. Terminal extubation with comfort-focused care (morphine for dyspnoea, midazolam for distress) prioritises patient dignity and family support over life prolongation.
• Extracorporeal CO₂ removal (ECCO₂R): Lower-flow extracorporeal systems that remove CO₂ (without full VV-ECMO oxygenation capacity) are being evaluated to facilitate ultra-low tidal volume ventilation (3–4 mL/kg IBW) in ARDS, further reducing VILI below what is achievable with standard LPV. The SUPERNOVA and REST trials investigated ECCO₂R in ARDS, with results showing feasibility but no mortality benefit in the REST trial — suggesting ECCO₂R should remain investigational until larger trials demonstrate clinical benefit.